BioSpace News Archive

Diabetes is a chronic disease that affects more than 8.5% of the global population. Monitoring the blood glucose levels on a regular basis is necessary to manage diabetes progression.

A treatment option with a novel mechanism of action for anti-aquaporin-4 seropositive neuromyelitis optica spectrum disorder (NMOSD) approved in the U.S.

Novavax, Inc., a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced the beginning of a Phase 2b clinical trial in South Africa to evaluate the efficacy of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate.

International medical imaging IT and cybersecurity company Sectra will install its enterprise imaging solution throughout Michigan Medicine.

DaVita Inc. announced that it has commenced a modified “Dutch auction” tender offer for shares of its common stock for an aggregate purchase price of up to $1.0 billion at a price per share of not less than $77.00 and not more than $88.00.

Enterprise Therapeutics Ltd, a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease, announced it has successfully dosed the first subjects in a Phase 1 trial for its novel inhaled cystic fibrosis therapy, ETD002.

United Therapeutics Corporation announced that the U.S. Food and Drug Administration accepted for review the supplemental New Drug Application for Tyvaso® Inhalation Solution for the treatment of pulmonary hypertension associated with interstitial lung disease.

Anti-Amyloid Agents that Block Toxicity of Soluble Amyloid Oligomers – A Key Driver of Alzheimer’s Disease – Show Positive Clinical Effects and Consistent Biomarker Results

Patent Application Relates to Production of Adeno-Associated Virus (AAV) via Use of LinearDNA™ Amplicons; AAV Viral Vectors Used in Gene and Redirected Cell Therapies; Current Production of AAV Relies Heavily on Use of Plasmid-derived DNA

Emergent BioSolutions Inc. announced that the U.S. Food and Drug Administration has approved the extension of the shelf life of NARCAN® Nasal Spray from 24 months to 36 months.